It's been awhile since Amylin stock price saw the following levels:
$20 - 16 months ago $30 - 42 months ago $40 - 52 months ago $50 - 53 months ago
The $20 lag is the hardest to accept considering Bydureon is nows approved, has been launched and yet $20 is still lagging. I hate dragging Dan Brdbury's name in the mud, but Dan Bradbury has been the CEO during the entire time.
Of course Amylin now has a big debt bill. This overhang values the co at $17 by most researchers.Amylin was close to being profitable before giving Lilly the boot.The stock price and covering is as expected imho- a partner with money up front,a buyout bid or positive acceptance of Bydureon are all factors for the future.The stock market of course values ALL stocks lower from the overpriced days of 2007.
Market correction? :Crawford perspectives has a great chart that shows the correlation of bullish peaks in the market and share price.Contrarain that I am,I believe we are a high point in that data.(or just turn on one of the financial channel talking heads. We need one of the above changes to revalue AMLN past 17 imho Good Luck
The shorts have it all in their favor and they patiently waited for the time, and here we are.I guarantee they have a better idea of why Amylin is not attending conferences and not PRing as a company moving ahead with a blockbuster should be acting.Im not worried a bit. Remember - many of the shorts are longs.They had to be hedged going into the FDA decision Good Luck